What is the prevalence of Antiphospholipid / Hughes Syndrome?

Antiphospholipid syndrome (APS), also known as Hughes syndrome, is a relatively rare autoimmune disorder that affects the blood clotting process. It is characterized by the presence of specific antibodies called antiphospholipid antibodies (aPL) in the blood, which can lead to an increased risk of abnormal blood clot formation.

The prevalence of APS varies across different populations and geographical regions. Estimates suggest that APS affects approximately 1-5% of the general population. However, it is important to note that many individuals with APS may remain undiagnosed due to its diverse and often nonspecific symptoms.

APS can occur at any age, but it is more commonly diagnosed in women of childbearing age. It is a leading cause of recurrent pregnancy loss and complications such as pre-eclampsia and fetal growth restriction. Additionally, APS can also manifest as blood clots in veins or arteries, leading to conditions like deep vein thrombosis or stroke.

Early diagnosis and appropriate management are crucial in APS to prevent complications. Treatment typically involves blood thinning medications to reduce the risk of clot formation. Regular monitoring and close collaboration with healthcare professionals are essential for individuals with APS to manage their condition effectively.